2013-10-16 14:37:13 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to TaiMed Biologics Inc. (4147) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering TaiMed Biologics Inc. (4147). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential TaiMed Biologics Inc. investor.
Report Summary: TaiMed Biologics Inc. is an average quality company with a positive outlook. TaiMed Biologics Inc. has medium business growth and is run by inefficient management. The trend in TaiMed Biologics Inc. fair value exchange rate against its closest rated-competitor, Mycenax Biotech Inc., has been appreciating over the past 2 weeks. When compared to its closest competitor, TaiMed Biologics Inc. shows similar undervaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of TaiMed Biologics Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.